journal article·2025-12Open access

Secondary Necrosis Following Caspase‐Activation can Occur Independently of Gasdermin E

Shubhangi Gavali, Francesca Maremonti, Wulf Tonnus, Florian Gembardt, Marlena Nastassja Schlecht, Karolin Flade, Anne von Mässenhausen, Stephen W. G. Tait, Stefan R. Bornstein, Andreas Linkermann

Advanced Science· Volume 12· Issue 46

Abstract

Abstract Regulated necrosis is a known direct consequence of activation of the necroptosis‐ and pyroptosis‐ pathways, but may also result from apoptosis in a process referred to as secondary necrosis. Apoptosis is well understood to be mediated by caspase activation, but the mechanisms that lead to plasma membrane rupture in secondary necrosis remain considerably obscure. Recent data suggested a caspase‐mediated cleavage of gasdermin E (GSDME), a member of the gasdermin family. Here, apoptosis induced by diphtheria toxin (DT) is employed as a novel tool to study secondary necrosis. In addition, cisplatin and anti‐Fas monoclonal antibody Jo2 are employed to study secondary necrosis in cell culture and in vivo, respectively. Despite prominent, yet epiphenomenal cleavage of GSDME, it is demonstrated that silencing or CRISPR/Cas9‐mediated knockout of GSDME does not compromise the kinetics of secondary necrosis induced by DT or cisplatin. During Jo2‐induced acute liver toxicity in mice, GSDME expressed in the necrotic liver is detected predominantly in its uncleaved form. In conclusion, the hypothesis of GSDME to be a central mediator of secondary necrosis in these model systems is disproved.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Cell death mechanisms and regulation · Toxin Mechanisms and Immunotoxins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medicine V University Medical Centre Mannheim University of Heidelberg 68167 Mannheim Germany

Department of Internal Medicine III University Hospital Carl Gustav Carus at the Technische Universität Dresden 01307 Dresden Germany

Institute of Clinical Chemistry and Clinical Pharmacology University Hospital Bonn 53127 Bonn Germany

Cancer Research UK Scotland Institute Glasgow 461 1BD UK

Diabetes and Nutritional Sciences King's College London London WC2R 2LS UK

Center for Regenerative Therapies Technische Universität Dresden 01307 Dresden Germany

Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Clinic Carl Gustav Carus of TU Dresden Faculty of Medicine 01307 Dresden Germany

Division of Nephrology Department of Medicine Albert Einstein College of Medicine Bronx NY 10467 USA

Funding

Deutsche Forschungsgemeinschaft · Bundesministerium für Bildung und Forschung

References (18)

Show source-provided references
1. 10.1038/s41418-023-01153-w10.1038/s41418-023-01153-w ↗
2. 10.1016/j.ymeth.2013.02.01110.1016/j.ymeth.2013.02.011 ↗
3. 10.1038/cdd.2009.18410.1038/cdd.2009.184 ↗
4. 10.1007/s00018-021-04078-010.1007/s00018-021-04078-0 ↗
5. 10.1038/ncomms1412810.1038/ncomms14128 ↗
6. 10.4049/jimmunol.149.6.208910.4049/jimmunol.149.6.2089 ↗
7. 10.1073/pnas.151286311210.1073/pnas.1512863112 ↗
8. 10.1128/MCB.00813-0910.1128/MCB.00813-09 ↗
9. 10.1038/364806a010.1038/364806a0 ↗
10. 10.1093/oxfordjournals.jbchem.a02219710.1093/oxfordjournals.jbchem.a022197 ↗
11. 10.1038/s41418-017-0012-410.1038/s41418-017-0012-4 ↗
12. 10.1038/nature0985210.1038/nature09852 ↗
13. 10.1084/jem.2023010510.1084/jem.20230105 ↗
14. 10.1038/nature2239310.1038/nature22393 ↗
15. 10.1038/ki.2013.20210.1038/ki.2013.202 ↗
16. 10.1084/jem.2006185210.1084/jem.20061852 ↗
17. 10.1002/eji.20134431510.1002/eji.201344315 ↗
18. 10.1084/jem.2018143910.1084/jem.20181439 ↗